Allscripts price target raised to $23 from $18 at Leerink Leerink raised its price target for Allscripts shares to $23 saying the company reported a high quality Q4 with bookings well ahead of expectations. The firm keeps an Outperform rating on the stock.
Allscripts extends agreement with Drexel University Drexel University College of Medicine renewed its agreement with Allscripts and the use of Allscripts TouchWorks EHR as its core electronic health record, or EHR, solution. In addition, Drexel implemented the Allscripts FollowMyHealth as its patient engagement platform. Drexel intends to leverage Allscripts solutions to help meet Meaningful Use requirements, support its mission of education and research, and continue to deliver high quality patient care for the communities it serves. Drexel's renewal extends an innovative relationship that began in 2004.
Allscripts and NoteSwift enter into collaboration agreement NoteSwift and Allscripts have entered into an agreement for Allscripts to market and resell NoteSwift 2.0 for Allscripts Professional EHR. In response to customer demand, this strategic agreement may help providers reduce the time spent on creating patient documentation by more than half through the use of medical speech recognition.